Figures & data
Table I. Patient and treatment characteristics.
Table II. Toxicity during neoadjuvant therapy, classified according to the WHO toxicity scheme.
Table III. Post-operative complications.
Table IV. Number of items assessed per domain of the GIQLI. The table depicts mean number and standard deviation of answered questions per domain of the GIQLI. TP1: before start of neoadjuvant therapy; TP2: after neoadjuvant therapy but before surgery; TP3: early after surgery; TP4: during long-term follow-up.
Figure 1. Global GIQLI score of patients during the treatment of advanced rectal cancer. TP1: before start of neoadjuvant therapy; TP2: after neoadjuvant therapy but before surgery; TP3: early after surgery; TP4: during long-term follow-up.
Table V. Global GIQLI score in uT3/uT4 rectum cancer patients before, during and after therapy. Reported scores are mean scores of the groups specified above.
Figure 2. GIQLI domains compared between patients undergoing neoadjuvant therapy with vs. without hyperthermia. (a) ‘symptoms of disease’; (b) ‘emotion’; (c) ‘physical function’; (d) ‘social life’; (e) ‘medical treatment’.
Figure 3. Global GIQLI scores of patients undergoing sphincter resection or sphincter preservation.
Table VI. Influence of postoperative complications and histopathological response on global GIQLI scores in uT3/uT4 rectum cancer patients.
Figure 4. Sexual impairment of patients with rectal cancer. Maximal obtainable point number was four points and corresponds to non-impaired sexual functioning; (a) male patients; (b) female patients.
